Abemaciclib is the newest cyclin-dependent kinase 4/6 inhibitor that has received approval from the US Food and Drug Administration for using in patients with advanced breast cancer. However, its potential adverse effects on cardiomyocytes remain unknown. In this study, we used the cell counting kit-8 assay, western blot analysis, flow cytometry, immunostaining, and quantitative polymerase chain reaction to investigate the role of abemaciclib in inducing apoptosis and in inhibiting the viability and proliferation of AC16 human cardiomyocyte cells. The results revealed that abemaciclib induced apoptosis and inhibited cell proliferation by activating the Hippo signaling pathway. This work demonstrates the molecular basis by which abemaciclib induces cardiac side effects, providing a theoretical basis and effective targets for the treatment of cardiac diseases.

中文翻译：

---

Abemaciclib通过激活Hippo信号通路诱导心肌细胞凋亡。

Abemaciclib是最新的细胞周期蛋白依赖性激酶4/6抑制剂，已获得美国食品和药物管理局的批准，可用于晚期乳腺癌患者。然而，其对心肌细胞的潜在不良影响仍然未知。在这项研究中，我们使用了细胞计数试剂盒8分析，蛋白质印迹分析，流式细胞仪，免疫染色和定量聚合酶链反应来研究abemaciclib在诱导细胞凋亡以及抑制AC16人心肌细胞活力和增殖中的作用。结果表明abemaciclib通过激活Hippo信号通路诱导细胞凋亡并抑制细胞增殖。这项工作证明了abemaciclib诱发心脏副作用的分子基础，